Achievements
The REVERT project successfully developed an innovative Clinical Decision Support System (AI-DSS) based on artificial intelligence to guide personalized treatment choices for patients with unresectable metastatic colorectal cancer (mCRC). Built through a unique multi-party approach, the AI-DSS integrates four independently developed algorithms to ensure transparency, reliability, and clinical trust. This explainable AI system was validated through a prospective clinical trial, which demonstrated improved progression-free. The platform was also made available to oncologists via a user-friendly mobile application, enabling real-time treatment recommendations based on patient-specific clinical, genomic, and molecular data.
In parallel, REVERT advanced precision oncology by integrating experimental data from patient-derived organoids with transcriptomic and biomarker analyses. These organoids were used to test drug sensitivity and validate the AI-DSS predictions, including the identification of novel response signatures to standard chemotherapy regimens (FOLFOX, FOLFIRI, FOLFOXIRI) and potential drug repurposing strategies.
The project also delivered several key exploitable results (KERs), including a harmonized clinical database (RDB), predictive models, and a decentralized platform for AI model sharing. These outputs not only enhanced clinical decision-making but also laid the groundwork for future commercialization and clinical adoption, especially through the active involvement of SMEs in the consortium.
Publications
The REVERT project has generated a wealth of scientific knowledge and technological innovation in the field of personalized medicine for metastatic colorectal cancer (mCRC). Our publications reflect the collaborative work of researchers, clinicians, and data scientists across Europe, and demonstrate the clinical relevance and scientific impact of REVERT’s AI-driven approach to treatment decision-making. All peer-reviewed articles are accessible through individual subpages, featuring scientific references and lay summaries for broader accessibility.
In addition to academic outputs, REVERT has delivered several key results that mark significant progress in precision oncology: from the development of a trustworthy, explainable AI Decision Support System (DSS) to the validation of patient-derived organoids for drug response prediction. These achievements represent important milestones toward more effective, personalized cancer therapies and support future clinical and technological innovation across Europe and beyond.
